Advertisement
Mayo Clinic Proceedings Home

Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes

Published:February 05, 2015DOI:https://doi.org/10.1016/j.mayocp.2014.12.014

      Abstract

      Objective

      To determine whether insulin delivered via a 4-mm × 32-gauge pen needle (PN) provides equivalent glycemic control as 8-mm × 31-gauge and 12.7-mm × 29-gauge PNs in obese (body mass index ≥30) patients with diabetes.

      Patients and Methods

      This prospective, multicenter, randomized, open-label, 2-period, crossover, equivalence, home-based study was conducted from October 26, 2010, through May 31, 2012. After a 3-week wash-in period, eligible patients aged 18 to 80 years with a hemoglobin A1c (HbA1c) level of 5.5% to 9.5% (37-80 mmol/mol) were randomized to compare either 4- vs 8-mm PNs or 4- vs 12.7-mm PNs, using each of the 2 assigned PNs for 12 weeks in random order. The primary outcome was change in HbA1c level, with equivalence limits of ±0.4%.

      Results

      The 274 patients randomized (mean ± SD age, 56.7±11.0 years) had a mean ± SD body mass index of 37.0±6.1 (range, 29.1-59.9) and took up to 350 U of insulin daily; 226 patients were included in the modified intention-to-treat analysis. Mean (95% CI) changes in HbA1c levels with the 4-mm PN were –0.08% (–0.21 to 0.06) and –0.10% (–0.19 to 0.00) vs the 8- and 12.7-mm PNs, respectively, within equivalence margins. The 4-mm PN was less painful than the larger PNs (P<.05), with similar leakage rates reported (4.1%-4.3%). Patients preferred the 4-mm PN over the 12.7-mm PN (P<.05) but not significantly vs the 8-mm PN. There were no differences between PNs in insulin doses and hypoglycemic or hyperglycemic adverse event rates.

      Conclusion

      The 4-mm × 32-gauge PN provides equivalent glycemic control as 8- and 12.7-mm PNs in obese patients with diabetes, with less pain and no increase in leakage. Shorter PNs should be considered in all insulin-requiring patients with diabetes, including those who are obese.

      Trial Registration

      Abbreviations and Acronyms:

      BMI (body mass index), HbA1c (hemoglobin A1c), mITT (modified intention-to-treat analysis), PN (pen needle), T1DM (type 1 diabetes mellitus), T2DM (type 2 diabetes mellitus), TDD (total daily dose (of insulin))
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cowie C.
        • Rust K.
        • Byrd-Holt D.
        • et al.
        Prevalence of diabetes and impaired fasting glucose in the U.S. population: National Health and Nutrition Examination Survey 1999-2002.
        Diabetes Care. 2006; 29: 1263-1268
        • Flegal K.
        • Carroll M.
        • Kit B.
        • Ogden C.
        Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.
        JAMA. 2012; 307: 491-497
        • Hu F.B.
        Globalization of diabetes: the role of diet, lifestyle and genes.
        Diabetes Care. 2011; 34: 1249-1257
        • Cheng Y.J.
        • Imperatore G.
        • Geiss L.S.
        • et al.
        Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010.
        Diabetes Care. 2013; 36: 2690-2696
        • Hart C.L.
        • Hole D.J.
        • Lawlor D.A.
        • Davey Smith G.
        How many cases of type 2 diabetes mellitus are due to being overweight in middle age? evidence from the Midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records.
        Diabet Med. 2007; 24: 73-80
        • Centers for Disease Control and Prevention (CDC)
        Prevalence of overweight and obesity among adults with diagnosed diabetes: United States, 1988-1994 and 1999-2002.
        MMWR Morb Mortal Wkly Rep. 2004; 53: 1066-1068
        • Hossain P.
        • Kawar B.
        • El Nahas M.
        Obesity and diabetes in the developing world: a growing challenge.
        N Engl J Med. 2007; 356: 213-215
        • Conway B.
        • Miller R.G.
        • Costacout T.
        • et al.
        Temporal patterns in overweight and obesity in Type 1 diabetes.
        Diabet Med. 2010; 27: 398-404
      1. Centers for Disease Control and Prevention. 2014 National diabetes statistics report. http://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html. Accessed November 7, 2014.

        • De Coninck C.
        • Frid A.
        • Gaspar R.
        • et al.
        Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey.
        J Diabetes. 2010; 2: 168-179
        • Ludescher B.
        • Rommel M.
        • Willmer T.
        • Fritsche A.
        • Schick F.
        • Machann J.
        Subcutaneous adipose tissue thickness in adults: correlation with BMI and recommendations for pen needle lengths for subcutaneous self-injection.
        Clin Endocrinol (Oxf). 2011; 75: 786-790
        • Hirsch L.J.
        • Gibney M.A.
        • Albanese J.
        • et al.
        Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes.
        Curr Med Res Opin. 2010; 26: 1531-1541
        • Schwartz S.
        • Hassman D.
        • Shelmet J.
        • et al.
        A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus.
        Clin Ther. 2004; 26: 1663-1678
        • Kreugel G.
        • Keers J.C.
        • Kerstens M.N.
        • Wolffenbuttel B.H.
        Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes.
        Diabetes Technol Ther. 2011; 13: 737-741
        • Hirsch L.J.
        • Gibney M.A.
        • Li L.
        • Berube J.
        Glycemic control, reported pain and leakage with a 4 mm x 32 G pen needle in obese and non-obese adults with diabetes: a post hoc analysis.
        Curr Med Res Opin. 2012; 28: 1305-1311
        • Strock E.
        • Bergenstal R.M.
        • Parvu V.
        • Hirsch L.
        • Gibney M.
        Glycemic control, pain and leakage with 4mm vs larger pen needles in obese patients treated with Lantus® or high insulin doses: pre-specified subgroup analyses.
        Diabetes. 2013; 62: A255
        • Tamborlane W.V.
        • Beck R.W.
        • Bode B.W.
        • et al.
        • Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group
        Continuous glucose monitoring and intensive treatment of type 1 diabetes.
        N Engl J Med. 2008; 359: 1464-1476
        • Birkebaek N.H.
        • Solvig J.
        • Hansen B.
        • Jorgensen C.
        • Smedegaard J.
        • Christiansen J.S.
        A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults.
        Diabetes Care. 2008; 31: e65
        • Wittmann A.
        • Kover J.
        • Kralj N.
        • et al.
        Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection.
        Diabetes Technol Ther. 2010; 12: 587-590
        • Hofmann P.L.
        • Derraik J.G.
        • Pinto T.E.
        • et al.
        Defining the ideal injection techniques when using 5-mm needles in children and adults.
        Diabetes Care. 2010; 33: 1940-1944
        • Ignaut D.A.
        • Fu H.
        Comparison of insulin diluent leakage postinjection using two different needle lengths and injection volumes in obese patients with type 1 or type 2 diabetes mellitus.
        J Diabetes Sci Technol. 2012; 6: 389-393
        • Miwa T.
        • Itoh R.
        • Kobayashi T.
        • et al.
        Comparison of the effects of a new 32-gauge x 4-mm pen needle and a 32-gauge x 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes.
        Diabetes Technol Ther. 2012; 14: 1084-1090
        • Nagai Y.
        • Ohshige T.
        • Arai K.
        • et al.
        Comparison between shorter straight and thinner microtapered insulin injection needles.
        Diabetes Technol Ther. 2013; 15: 550-555
        • Hirose T.
        • Ogihara T.
        • Tozaka S.
        • Kanderian S.
        • Watada H.
        Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6- and 8-mm needles, accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males.
        J. Diabetes Invest. 2013; 4: 287-296
        • de la Pena A.
        • Yeo K.P.
        • Catton E.
        • Ignaut D.A.
        Injection depth does not affect the pharmacokinetics or pharmacodynamics of insulin lispro in healthy obese or normal weight subjects.
        Diabetes. 2014; 63: A35
        • Frid A.
        • Hirsch L.
        • Gaspar G.
        • et al.
        New injection recommendations for patients with diabetes.
        Diabetes Metab. 2010; 36: S3-S18
        • LoPresti D.
        • Ingegnosi C.
        • Strauss K.
        Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection.
        Pediatr Diabetes. 2012; 13: 525-533
        • Gibney M.A.
        • Arce C.H.
        • Byron K.J.
        • Hirsch L.J.
        Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.
        Curr Med Res Opin. 2010; 26: 1519-1530
        • Hirsch L.
        • Byron K.
        • Gibney M.
        Intramuscular risk at insulin injection sites: measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy.
        Diabetes Technol Ther. 2014; 16: 867-873
        • Vaag A.
        • Handberg A.
        • Lauritzen M.
        • Henriksen J.E.
        • Pedersen K.D.
        • Beck-Nielsen H.
        Variation in absorption of NPH insulin due to intramuscular injection.
        Diabetes Care. 1990; 13: 74-76
        • Vaag A.
        • Pedersen K.D.
        • Lauritzen M.
        • Hilderbrandt P.
        • Beck-Nielsen H.
        Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type 1 diabetes mellitus.
        Diabet Med. 1990; 7: 335-342
        • Kramer H.
        • Cao G.
        • Dugas L.
        • Luke A.
        • Cooper R.
        • Durazo-Arvizu R.
        Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys.
        J Diabetes Complications. 2010; 24: 368-374